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Figure S1. Structure of compound 5b in the solid state; only one of two independent molecules present in 
the unit cell is shown for clarity 
 
X-ray Crystal Structure Analysis of 5b: (C23H28BClO3), Mr = 398.71  g·mol
-1, colorless plate, crystal size 0.327 x 
0.298 x 0.050 mm3, triclinic, space group P1¯, a = 9.8066(2) Å, b = 10.5520(3) Å, c = 21.6009(6) Å,  = 
103.3530(10)°,  = 92.0280(10)°,  = 99.6610(10)°, V = 2137.56(10) Å3, T = 100(2) K, Z = 4, Dcalc = 1.239  g·cm
3, 
 = 1.54178 Å, (Cu-K) = 1.736 mm
-1, Gaussian absorption correction (Tmin = 0.63, Tmax = 0.93), Bruker AXS X8 
Proteum diffractometer, 4.900 <  < 72.472°, 40538 measured reflections, 7914 independent reflections, 
6551 reflections with I > 2σ(I), Rint = 0.0529.  
The structure was solved by direct methods and refined by full-matrix least-squares against F2 to R1 = 0.047 [I 
> 2(I)], wR2 = 0.112, 561 parameters. Several low-angle reflections were shadowed by the beamstop and 
were omitted before the final refinement cycles.  
The H atoms were refined using a rotational group riding model, S = 1.028, residual electron density 0.3/0.5 





Figure S2. Structure of compound 5n in the solid state; only one of the two antipodal molecules present in 
the unit cell is shown for clarity 
 
X-ray Crystal Structure Analysis of 5n: (C20H27BClF3O3), Mr = 418.67  g·mol
-1, colorless prism, crystal size 
0.144 x 0.111 x 0.092 mm3, triclinic, space group P1¯, a = 9.1295(10) Å, b = 11.2795(13) Å, c = 21.152(3) Å,  = 
99.045(2)°,  = 95.674(5)°,  = 91.865(2)°, V = 2138.0(5) Å3, T = 100(2) K, Z = 4, Dcalc = 1.301  g·cm
3,  = 
0.71073 Å, (Mo-K) = 0.221 mm
-1, Gaussian absorption correction (Tmin = 0.97, Tmax = 0.98), Bruker AXS Enraf-
Nonius KappaCCD diffractometer, 1.961 <  < 33.142°, 65114 measured reflections, 16259 independent 
reflections, 13805reflections with I > 2σ(I), Rint = 0.0243.  
The structure was solved by direct methods and refined by full-matrix least-squares against F2 to R1 = 0.039 [I 
> 2(I)], wR2 = 0.109, 527 parameters. Several low-angle reflections were shadowed by the beamstop and 
were omitted before the final refinement cycles.  
Hydroxyl H atoms were found and refined. Otherwise, H atoms were refined using a riding model, S = 1.025, 





Figure S3. Structure of compound 10i in the solid state; two co-crystallized [D4]-MeOH molecules are not 
shown for clarity 
 
X-ray Crystal Structure Analysis of 10i: (C36H44D8BClO6), Mr = 635.08  g·mol
-1, colorless prism, crystal size 
0.260 x 0.169 x 0.103 mm3, monoclinic, space group P21, a = 9.4553(4) Å, b = 11.9148(5) Å, c = 16.3010(6) Å, 
 = 106.060(2)°, V = 1764.77(12) Å3, T = 100(2) K, Z = 2, Dcalc = 1.195  g·cm
3,  = 1.54178 Å, (Cu-K) = 1.289 
mm-1, Gaussian absorption correction (Tmin = 0.85, Tmax = 0.91), Bruker AXS X8 Proteum diffractometer, 2.821 
<  < 72.228°, 68680 measured reflections, 6357 independent reflections, 5764 reflections with I > 2σ(I), Rint 
= 0.0514, Absolute structure parameter = 0.014(15).  
The structure was solved by direct methods and refined by full-matrix least-squares against F2 to R1 = 0.033 [I 
> 2(I)], wR2 = 0.082, 419 parameters. Several low-angle reflections were shadowed by the beamstop and 
were omitted before the final refinement cycles.  
Hydroxy-H atoms were found and refined. Otherwise, H atoms were refined using a riding model, S = 1.110, 






Figure S4. Structure of 1,2-oxaborolol derivative 3b in the solid state 
 
X-ray Crystal Structure Analysis of 3b: (C17H23B2ClO4), Mr = 348.42  g·mol
-1, colorless prism, crystal size 0.153 
x 0.095 x 0.021 mm3, monoclinic, space group P21/n, a = 6.4123(12) Å, b = 16.923(3) Å, c = 17.041(3) Å,  = 
100.090(4)°, V = 1820.6(6) Å3, T = 100(2) K, Z = 4, Dcalc = 1.271  g·cm
3,  = 0.71073 Å, (Mo-K) = 0.227 mm
-1, 
Gaussian absorption correction (Tmin = 0.43, Tmax = 0.84), Bruker AXS Enraf-Nonius KappaCCD diffractometer, 
2.407 <  < 30.533°, 47844 measured reflections, 5551 independent reflections, 4565 reflections with I > 
2σ(I), Rint = 0.0545.  
The structure was solved by direct methods and refined by full-matrix least-squares against F2 to R1 = 0.040 [I 
> 2(I)], wR2 = 0.107, 224 parameters. Several low-angle reflections were shadowed by the beamstop and 
were omitted before the final refinement cycles.  
The H atoms were refined using a rotational group riding model, S = 1.032, residual electron density 0.5/0.4 









Entry  Base Pd catalyst Ligand  PhX Solvent Yield (%)
a
 
1 n-BuLi Pd(OAc)2 dppf
d
 PhOTf THF 0 
2 LiTMP Pd(OAc)2 dppf
d
 PhOTf THF 0 
3 LiHMDS Pd(OAc)2 dppf
d
 PhOTf THF 10 




 THF 31 




 THF 37 




 THF 0 




 THF 10 




 THF 20 
9 NaHMDS Pd2(dba)3 P(o-tol)3 PhI 1,4-dioxane < 5 




 1,4-dioxane 62 (66)
b
 




 1,4-dioxane < 5
b
 




 1,4-dioxane < 5
b
 




 1,4-dioxane < 5
b
 






 1,4-dioxane 33 




 1,4-dioxane 68 




 1,4-dioxane 73 



















Entry Variations on the standard condition Yield (%)
a
 
1 none 62 
2 dioxane as solvent 15 
3 without THF 0 










Entry  Catalyst Ligand  Solvent Yield (%)
a
 
1 Pd2(dba)3 P(o-tol)3 THF 34 (25)
b
 
2 Pd2(dba)3 P(o-tol)3 1,4-dioxane 67 
3 Pd2(dba)3 P(2-furyl)3 1,4-dioxane 36 









LiHMDS instead of NaHMDS. 
C
1.5 equiv. MeI was used. 
d





Entry  Catalyst Ligand  Solvent Yield (%)
a
 
1 Pd2(dba)3 P(2-furyl)3 1,4-dioxane 78 
2 Pd2(dba)3 XPhos 1,4-dioxane 17 
3 Pd2(dba)3 DPEPhos
b
 PhMe/THF (10 equiv.) 44 
4 Pd2(dba)3 P(2-furyl)3 PhMe/THF (10 equiv.) 90 
5 Pd2(dba)3 P(2-furyl)3 PhMe 68 
5 CuCl Xantphos
d









11B NMR: Evidence that intermediate 2b is (largely) in the borate state  
 
 
PROCEDURES AND CHARACTERIZATION DATA 
General Methods: Unless stated otherwise, all reactions were carried out under Argon atmosphere 
in flame-dried glassware. The solvents were purified by distillation over the indicated drying agents 
under Argon: THF, 1,4-dioxane, hexane, toluene (Na/K); CH2Cl2 (CaH2) and 1,2-dichloroethane 
(CaH2) were stored over molecular sieves and degassed via three freeze-pump-thaw cycles. If not 
mentioned otherwise, NMR spectra were recorded at room temperature using either a Bruker DPX 
300, AMX 300 or AV 400 spectrometer in the solvents indicated. Chemical shifts () are given in ppm 
and coupling constants (J) in Hz. The following abbreviations are used to indicate the signal 
multiplicity: s (singlet), brs (broad singlet), d (doublet), t (triplet), q (quartet) and m (multiplet) as well 
as combinations of them. Mass spectra (MS and HRMS) were determined using either a Finnigan 
MAT 8200 (70 eV), ESI-MS: ESQ 3000 (Bruker), Bruker APEX III FT-MS (7 T magnet) or MAT 95 
(Finnigan) spectrometer. Infrared Spectroscopy (IR): Spectrum One Perkin Elmer, wavenumbers (?̃?) 
in cm
-1
. Flash chromatography was carried out using Merck silica gel 60 (40-63 μm) using the 
indicated eluents. Analytical Thin Layer Chromatography (TLC) was carried out on precoated 
Macherey-Nagel plates (POLYGRAM
®
 SIL G/UV254). Preparative TLC: Macherey-Nagel precoated 









nm), KMnO4 (in 1.5M Na2CO3 (aq.)), molybdatophosphoric acid (5 % in ethanol), vanillin/H2SO4 (in 
ethanol) or anisaldehyde/HOAc (in ethanol).  
 
Starting Materials 
Propargyl alcohols and diaryl iodonium triflates were purchased from Sigma-Aldrich, ABCR, or TCI, 
or were prepared in analogy to the literature procedures cited below: 
3-Methyl-1-(2-methylphenyl)pent-1-yn-3-ol (S1).
[1]
 Colorless oil (344 mg, 91%); 
1
H NMR (400 MHz, 
CD3OD) δ = 7.37-7.29 (m, 1 H), 7.23-7.16 (m, 2 H), 7.15-7.07 (m, 1 H), 2.41 (s, 
3 H), 1.88-1.66 (m, 2 H), 1.53 (s, 3 H), 1.11 (t, J = 7.2 Hz, 3 H) ppm; 
13
C NMR 
(101 MHz, CD3OD) δ = 139.6, 131.4, 129.0, 127.8, 125.2, 122.7, 96.8, 81.2, 68.3, 
36.3, 28.3, 19.4, 8.2 ppm;
 
IR (ATR): ṽ = 3363, 2972, 2934, 1485, 1456, 1370, 
1155, 1125, 1033, 995, 906, 754, 716 cm
-1
; HRMS (EI) m/z calcd for [C13H16O]
+









(400 MHz, CD3OD) δ = 7.34-7.26 (m, 2 H), 7.20-7.11 (m, 2 H), 2.63 (q, J 
= 7.6 Hz, 2 H), 2.04-1.87 (m, 2 H), 1.79-1.52 (m, 7 H), 1.36-1.25 (m, 1 H), 
1.22 (t, J = 7:6 Hz, 3 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 144.4, 
131.1, 127.5, 120.3, 91.9, 83.6, 68.0, 39.6, 28.3, 25.0, 23.0, 14.5 ppm;
 
IR 
(ATR): ṽ = 3197, 2927, 2854, 1510, 1448, 1345, 1297, 1186, 1071, 965, 827, 682, 548 cm-1; HRMS 
(EI) m/z calcd for [C16H20O]
+
: 228.1509; found: 228.1510.  
(Z)-8-Methylnon-5-en-3-yn-2-ol (S3).
[2]
 Colorless oil (390 mg, 85%); 
1
H NMR (400 MHz, CDCl3) δ = 
5.89-5.77 (m, 1 H), 5.45-5.36 (m, 1 H), 4.63-4.47 (m, 1 H), 2.14-2.03 (m, 2 H), 1.73 
(brs, OH), 1.67-1.54 (m, 1 H), 1.38 (d, J = 6.4 Hz, 3 H), 0.82 (d, J = 6.8 Hz, 6 H) 
ppm; 
13
C NMR (101 MHz, CDCl3) δ = 143.3, 109.0, 94.9, 81.1, 58.9, 39.2, 28.3, 
24.5, 22.4 ppm;
 
IR (ATR): ṽ = 3318, 2956, 2929, 2871, 1464, 1368, 1330, 1278, 1154, 1121, 1073, 
1015, 985, 884, 828, 729, 641 cm
-1
; HRMS (ESI) m/z calcd for [C10H16O+Na]
+
: 175.1093; found: 
175.1094.  
9-Methyldeca-4,6-diyne-1,8-diol (S4).




H NMR (400 MHz, 
CD3OD) δ = 4.05 (d, J = 6.0 Hz, 1 H), 3.56 (t, J = 6.4 Hz, 2 H), 2.41-2.25 
(m, 2 H), 1.82-1.58 (m, 3 H), 0.99-0.83 (m, 6 H) ppm; 
13
C NMR (101 
MHz, CD3OD) δ = 79.4, 75.6, 69.2, 67.2, 64.3, 59.9, 34.6, 30.8, 17.2, 
16.6, 14.9 ppm;
 
IR (ATR): ṽ = 3301, 3217, 2958, 2874, 2255, 1463, 1317, 1166, 1057, 1025, 896, 684 
cm
-1
; HRMS (ESI) m/z calcd for [C11H16O2+Na]
+





decahydro-6H-cyclopenta[a]phenanthren-17-ol (S5).[4] Pale yellow solid 




H NMR (400 MHz, CD3OD) δ = 7.38 
(d, J = 8.4 Hz, 2 H), 7.32 (d, J = 8.4 Hz, 2 H), 7.17 (d, J = 8.4 Hz, 1 H 
), 6.65 (d, J = 8.4 Hz, 1 H), 6.58 (s, 1 H), 3.72 (s, 3 H), 2.94-2.68 (m, 
2 H), 2.49-2.24 (m, 2 H), 2.23-1.69 (m, 7 H), 1.55-1.20 (m, 4 H), 0.91 
(s, 3 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 157.5, 137.4, 133.7, 132.5, 132.1, 128.3, 125.9, 
121.9, 113.2, 111.0, 94.2, 83.8, 79.4, 54.1, 49.8, 47.4, 43.7, 39.7, 38.5, 33.0, 29.4, 27.2, 26.3, 22.4, 
12.1 ppm; IR (ATR): ṽ = 3421, 2927, 2867, 1608, 1488, 1453, 1252, 1234, 1090, 1039, 1013, 826, 
781, 527 cm
-1
; HRMS (ESI) m/z calcd for [C27H29ClO2+Na]
-
: 443.1748; found: 443.1749. 
(4E,6E)-1-(3-(Trifluoromethyl)phenyl)octa-4,6-dien-1-yn-3-ol (S6).
[1]
 Semi-solid (479 mg, 90%, contains 
11 % Z,Z-isomer); 1H NMR (400 MHz, CD3OD) δ = 7.74-7.60 (m, 3 
H), 7.57-7.49 (m, 1 H), 6.45-6.32 (m, 1 H), 6.18-6.01 (m, 1 H), 5.86-
5.74 (m, 1 H), 5.74-5.64 (m, 1 H), 5.06 (d, J = 6.4 Hz, 1 H), 1.81-1.72 
(m, 3 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 134.7 (d, J = 0.8 Hz), 
131.9, 130.7, 130.6 (q, J = 32 Hz), 130.3, 129.1, 128.8, 127.7 (q, J = 4.0 Hz), 124.6 (q, J = 3.8 Hz), 
123.9, 123.8 (q, J =270 Hz), 90.4, 82.9, 62.0, 16.9 ppm; IR (ATR): ṽ = 3350, 2207, 1650, 1610, 1433, 
1330, 1166, 1123, 1071, 985, 902, 801, 694, 659 cm
-1
; HRMS (CI Ammonia) m/z calcd for 
[C15H12F3O+NH3]
-
: 282.1111; found: 282.1102. 
(E)-1-(4-Chlorophenyl)hept-4-en-1-yn-3-ol (S7).
[1]





(400 MHz, CD3OD) δ = 7.41 (d, J = 8.4 Hz, 2 H), 7.36 (d, J = 8.4 Hz, 2 H), 
6.03-5.86 (m, 1 H), 5.70-5.57 (m, 1 H), 4.98 (d, J = 6.4 Hz, 1 H), 2.19-2.04 
(m, 2 H), 1.05 (t, J = 7.2 Hz, 3 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 
134.4, 134.0, 132.6, 128.3, 128.2, 121.6, 89.9, 83.2, 62.3, 24.6, 12.2 ppm;
 
IR (ATR): ṽ = 3223, 2964, 2874, 1669, 1487, 1296, 1251, 1089, 993, 962, 828, 766, 735, 521 cm-1; 
HRMS (EI) m/z calcd for [C13H13ClO]
+
: 220.0649; found: 220.0646. 
trans-Carboboration Reactions 
Representative Procedure for trans-Arylboration. Preparation of (Z)-4-(4-Chlorophenyl)-2-methyl-4-
phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-3-en-2-ol (5d). A flame-dried tube 
equipped with a magnetic stir bar was charged under Ar with THF (0.2 mL), 2-methyl-4-
phenylbut-3-yn-2-ol (32 mg, 0.2 mmol,), and NaHMDS (36.7 mg, 0.2 mmol). B2Pin2 
(55.8 mg, 0.22 mol,), 1,2-dichloroethane (2 mL), Pd2(dba)3 (9.1 mg, 0.01 mmol), tri(2-
furyl)phosphine (9.2 mg, 0.04 mmol) and bis(4-chlorophenyl) iodonium triflate (200 mg, 
0.4 mmol) were sequentially added. The tube was sealed and the mixture stirred at 60 
o
C (bath 
temperature) for 18 h. After cooling to room temperature, the reaction was quenched with aq. sat. 
NH4Cl (2  mL), the aqueous phase was extracted by EtOAc (3 x 5 mL), and the combined organic 
S11 
 
layer were dried (NaSO4), filtered and evaporated. The residue was purified by flash chromatography 
(SiO2, hexanes/EtOAc) or thin layer chromatography to provide the title compound as a white solid 




H NMR (400 MHz, CD3OD) δ = 7.33-7.26 (m, 4 H), 7.25-7.14 (m, 
5 H), 1.26 (s, 6 H), 1.02 (s, 12 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 144.7, 144.2, 141.8, 132.1, 
129.9, 128.7, 127.6, 127.5, 126.6, 83.3, 73.6, 30.1, 23.7 ppm; 
11
B NMR (128 MHz, CD3OD) δ = 30.0 
ppm; IR (ATR): ṽ = 2975, 2931, 1622, 1488, 1335, 1303, 1265, 1138, 1092, 1013, 962, 835, 760, 696, 
637, 541 cm
-1
; HRMS (ESI) m/z calcd for [C23H28ClBO3+Na]
+
: 421.1712; found: 421.1715. 
The following compounds were prepared analogously: 
4,4-Diphenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-3-en-2-ol (5a). White solid (51 




H NMR (400 MHz, CD3OD) δ = 7.38-7.30 (m, 2 H), 7.30-
7.14 (m, 8 H), 5.80-5.71 (m, 1 H), 4.53 (q, J = 6.4 Hz, 1 H), 1.31 (d, J = 6.4 Hz, 3 H), 
1.19 (s, 6 H), 1.12 (s, 6 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 149.1, 143.9, 141.7, 
128.7, 128.6, 127.9, 127.5, 126.9, 126.7, 83.4, 68.9, 23.9, 23.7, 21.9 ppm; 
11
B NMR (128 MHz, 
CD3OD) δ = 30.9 ppm; IR (ATR): ṽ = 2977, 2927, 2559, 1614, 1491, 1443, 1358, 1291, 1142, 1126, 
1069, 929, 851, 766, 704, 638, 596 cm
-1









H NMR (400 MHz, 
CD3OD) δ = 7.38-7.10 (m, 9 H), 1.21 (s, 6 H), 1.04 (s, 12 H) ppm; 
13
C NMR (101 
MHz, CD3OD) δ = 144.6, 143.2, 142.5, 132.3, 130.3, 128.3, 127.6, 127.4, 126.4, 
83.3, 73.8, 29.9, 23.6 ppm; 
11
B NMR (128 MHz, CD3OD) δ = 30.0 ppm; IR (ATR): ṽ = 3483, 2974, 
2932, 1480, 1369, 1329, 1280, 1141, 1083, 1011, 940, 848, 801, 766, 702, 658, 598, 541 cm
-1
; HRMS 
(EI) m/z calcd for [C23H27BClO3]

: 397.1747; found: 397.1747. 
(E)-4-(4-Trifluoromethylphenyl)-2-methyl-4-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-




H NMR (400 
MHz, CD3OD) δ = 7.58-7.43 (m, 4 H), 7.36-7.26 (m, 2 H), 7.26-7.17 (m, 3 H), 
1.23 (s, 6 H), 1.00 (s, 12 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 148.5, 144.5, 
142.1, 129.3, 128.5 (q, J = 32 Hz), 128.3, 127.8, 126.6, 124.33 (q, J = 269 Hz), 124.34 (q, J = 3.9 Hz), 
83.3, 73.8, 29.8, 23.6 ppm; 
11
B NMR (128 MHz, CD3OD) δ = 29.9 ppm; IR (ATR): ṽ = 3571, 2980, 
2931, 1612, 1382, 1326, 1300, 1161, 1138, 1107, 1065, 1029, 961, 849, 708, 675, 615, 546, 499 cm
-1
; 
HRMS (ESI) m/z calcd for [C24H28BF3O3+Na]
+
: 455.1975; found: 455.1980. 
(Z)-4-(4-Fluorophenyl)-2-methyl-4-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxa-





(400 MHz, CD3OD) δ = 7.32-7.26 (m, 2 H), 7.26-7.14 (m, 5 H), 7.08-6.99 (m, 2 H), 1.25 
(s, 6 H), 1.02 (s, 12 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 162.9, 160.5, 144.7 (d, J 
S12 
 
= 51.7 Hz), 139.1 (d, J = 3.7 Hz), 130.0 (d, J = 8.1 Hz), 128.7, 127.5, 126.5, 114.2 (d, J = 21.4 Hz), 
83.3, 73.6, 30.0, 23.6 ppm; 
11
B NMR (128 MHz, CD3OD) δ = 30.1 ppm; IR (ATR): ṽ = 2979, 2938, 
2577, 1599, 1503, 1371, 1330, 1288, 1216, 1142, 1041, 964, 854, 736, 699, 639, 560, 529 cm
-1
; 
HRMS (ESI) m/z calcd for [C23H28FBO3+Na]
+
: 405.2007; found: 405.2011. 
(Z)-2-Methyl-4-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(p-tolyl)but-3-en-2-ol 




H NMR (400 MHz, CD3OD) δ = 7.19-
7.14 (m, 2 H), 7.11-7.02 (m, 3 H), 7.01-6.95 (m, 4 H), 2.12 (s, 3 H), 1.11 (s, 6 H), 0.90 
(s, 12 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 146.1, 144.8, 140.0, 135.9, 128.7, 
128.2, 128.1, 127.3, 126.3, 83.2, 73.9, 30.0, 23.7, 19.8 ppm; 
11
B NMR (128 MHz, 
CD3OD) δ = 30.3 ppm; IR (ATR): ṽ = 2978, 2928, 2547, 1508, 1371, 1339, 1299, 1144, 
1109, 1044, 964, 849, 728, 694, 635, 560, 525 cm
-1
; HRMS (ESI) m/z calcd for [C24H31BO3+Na]
+
: 
401.2258; found: 401.2263.  
(Z)-4-(4-Bromophenyl)-4-(4-methoxyphenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-





(400 MHz, CD3OD) δ = 7.54-7.40 (m, 2 H), 7.16-6.98 (m, 4 H), 6.86-6.73 (m, 2 
H), 4.44 (q, J = 6.4 Hz, 1 H), 3.75 (s, 3 H), 1.28 (d, J = 6.4 Hz, 3 H), 1.19 (s, 6 H), 
1.13 (s, 6 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 159.4, 147.4, 141.1, 136.0, 
130.9, 130.6, 129.9, 120.5, 112.9, 83.4, 68.9, 54.3, 23.9, 23.7, 21.9 ppm; 
11
B 
NMR (128 MHz, CD3OD) δ = 31.1 ppm; IR (ATR): ṽ = 3482, 2976, 2931, 1737, 1606, 1509, 1300, 
1243, 1132, 1034, 849, 829, 817, 758, 618 cm
-1
; HRMS (ESI) m/z calcd for [C23H28BrBO4+Na]
+
: 
481.1156; found: 481.1158. 
(1E,4E)-1-(4-Chlorophenyl)-1-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hepta-1,4-




H NMR (400 
MHz, CD2Cl2) δ = 7.36-7.29 (m, 2 H), 7.10-6.92 (m, 6 H), 2.47 (q, J = 7.6 
Hz, 2 H), 1.63-1.27 (m, 11 H), 1.06 (t, J = 7.6 Hz, 3 H), 0.89 (s, 12 H) ppm; 
13
C NMR (101 MHz, CD2Cl2) δ = 145.2, 143.4, 142.8, 141.8, 131.0, 130.1, 
128.7, 127.4, 120.3, 83.4, 75.2, 38.0, 28.5, 25.3, 24.4, 21.5, 15.7 ppm; 
11
B 
NMR (128 MHz, CD2Cl2) δ = 29.9 ppm; IR (ATR): ṽ = 2928, 2846, 1483, 1372, 1337, 1302, 1140, 
1069, 1013, 969, 885, 850, 822, 751, 611 cm
-1
; HRMS (ESI) m/z calcd for [C28H36BBrO3+Na]
+
: 
533.1833; found: 533.1840. 
(Z)-2-Methyl-4-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oct-3-en-2-ol (5i). White 




H NMR (400 MHz, C6D6) δ = 7.04-6.99 (m, 4 H), 6.98-6.91 (m, 1 
H), 2.45 (t, J = 8 Hz, 2 H), 1.78 (brs, OH), 1.47-1.36 (m, 2 H), 1.33-1.21 (m, 8 H), 
1.15 (s, 12 H), 0.81 (t, J = 7.6 Hz, 3 H) ppm; 
13
C NMR (101 MHz, C6D6) δ = 145.1, 
143.3, 128.5, 126.2, 82.9, 74.1, 41.3, 31.2, 30.8, 24.8, 22.8, 14.0 ppm; 
11
B NMR 
(128 MHz, C6D6) δ = 30.6 ppm; IR (ATR): ṽ = 2974, 2930, 2860, 1630, 1467, 1378, 1339, 1294, 
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1141, 1060, 963, 845, 771, 716, 665, 528 cm
-1
; HRMS (ESI) m/z calcd for [C21H33BO3+Na]
+
: 
367.2415; found: 367.2417. 
(Z)-4-(Cyclohex-1-en-1-yl)-2-methyl-4-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-




H NMR (400 
MHz, CD3OD) δ = 7.32-7.16 (m, 3 H), 7.12-7.04 (m, 2 H), 5.80-5.70 (m, 1 H), 2.11-
1.99 (m, 2 H), 1.95-1.84 (m, 2 H), 1.53-1.43 (m, 4 H), 1.29 (s, 12 H), 1.10 (s, 6 H), 
ppm; 
13
C NMR (101 MHz, CD3OD) δ = 149.0, 143.0, 141.2, 128.5, 127.1, 126.2, 123.9, 83.1, 73.5, 
30.1, 26.7, 25.0, 24.2, 22.2, 21.6 ppm; 
11
B NMR (128 MHz, CD3OD) δ = 30.3 ppm; IR (ATR): ṽ = 
2974, 2938, 1724, 1447, 1365, 1201, 1144, 1081, 982, 850, 756, 699, 672 cm
-1
; HRMS (ESI) m/z 
calcd for [C23H33BO3+Na]
+
: 391.2415; found: 391.2416. 
(Z)-1-(Cyclohex-1-en-1-yl)-1-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pent-1-en-3-
ol (5k). Colorless oil (48 mg, 70%); 
1
H NMR (400 MHz, CD3OD) δ = 7.36-7.29 
(m, 2 H), 7.28-7.21 (m, 1 H), 7.20-7.14 (m, 2 H), 5.80-5.71 (m, 1 H), 4.10 (t, J = 7.2 
Hz, 1 H), 2.16-2.07 (m, 2 H), 1.97-1.70 (m, 2 H), 1.71-1.51 (m, 6 H), 1.31 (s, 6 H), 
1.30 (s, 6 H), 0.70 (t, J = 7.6 Hz, 3 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 154.0, 143.1, 140.0, 
128.4, 127.6, 126.6, 124.7, 83.1, 73.6, 29.4, 26.9, 25.1, 24.2, 23.8, 22.3, 21.8, 9.5 ppm; 
11
B NMR (128 
MHz, CD3OD) δ = 30.9 ppm; IR (ATR): ṽ = 2975, 2928, 1443, 1354, 1295, 1134, 1083, 963, 853, 
772, 703, 667, 608 cm
-1
; HRMS (ESI) m/z calcd for [C23H33BO3+Na]
+
: 391.2415; found: 391.2417. 
(E)-2-Methyl-4-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)undec-3-en-5-yn-2-ol (5l). 
Colorless oil (34 mg, 51%); 
1
H NMR (400 MHz, CD3OD) δ = 7.34-7.21 (m, 
3 H), 7.21-7.13 (m, 2 H), 2.23 (t, J = 6.8 Hz, 2 H), 1.52-1.39 (m, 2 H), 1.35 
(s, 12 H), 1.32-1.27 (m, 4 H), 1.12 (s, 6 H), 0.86 (t, J = 7.2 Hz, 3 H) ppm; 
13
C 
NMR (101 MHz, CD3OD) δ = 140.7, 128.1, 127.6, 126.7, 126.6, 91.6, 83.6, 82.9, 73.5, 30.8, 29.6, 
28.1, 23.9, 21.8, 18.9, 12.9 ppm; 
11
B NMR (128 MHz, CD3OD) δ = 30.0 ppm; IR (ATR): ṽ = 2974, 
2931, 2860, 1587, 1463, 1369, 1347, 1297, 1143, 1040, 964, 848, 725, 701, 669, 613 cm
-1
; HRMS 
(ESI) m/z calcd for [C24H35BO3+Na]
+
: 405.2571; found: 405.2573. 
(1E,4E)-1-(4-chlorophenyl)-1-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hepta-1,4-
dien-3-ol (5m). The reaction was carried out in 1,4-dioxane instead of 1,2-





(400 MHz, CD2Cl2) δ = 7.30-7.09 (m, 5 H), 7.08-6.97 (m, 4 H), 5.65-5.47 (m, 
2 H), 4.56-4.45 (m, 1 H), 2.70 (d, J = 8.8 Hz, 1 H), 2.07-1.91 (m, 2 H), 1.09 (s, 6 H), 1.03 (s, 6 H), 
0.92 (t, J = 7.6 Hz, 3 H) ppm; 
13
C NMR (101 MHz, CD2Cl2) δ = 149.1, 143.9, 141.7, 128.7, 128.6, 
127.9, 127.5, 126.9, 126.7, 83.4, 68.9, 23.9, 23.7, 21.9 ppm; 
11
B NMR (128 MHz, CD2Cl2) δ = 30.8 
ppm; IR (ATR): ṽ = 2976, 2927, 1592, 1485, 1349, 1312, 1246, 1140, 1085, 1012, 962, 848, 765, 700, 
608 cm
1
; HRMS (ESI) m/z calcd for [C25H30BClO3+Na]
+








H NMR (400 
MHz, CD2Cl2) δ = 7.36-7.24 (m, 2 H), 7.14-7.02 (m, 2 H), 3.87 (d, J = 6.4 Hz, 1 H), 
2.30 (d, J = 6.4 Hz, 1 H), 1.26 (s, 6 H), 1.25 (s, 6 H), 0.71 (s, 9 H) ppm; 
13
C NMR 
(101 MHz, CD2Cl2) δ = 137.4 (q, J = 29.4 Hz), 134.4, 132.5, 131.2, 128.6, 123.2 (q, J 
= 273 Hz), 84.9, 79.7, 36.4, 26.2, 25.2, 24.9 ppm; 
11
B NMR (128 MHz, CD2Cl2) δ = 
30.1 ppm; IR (ATR): ṽ = 3501, 2961, 1491, 1307, 1200, 1164, 1119, 1087, 1015, 961, 826, 736, 576 
cm
-1
; HRMS (ESI) m/z calcd for [C20H27F3ClBO3+Na]
+
: 441.1586; found: 441.1587. 
Representative Procedure for trans-Methylboration. Preparation of (E)-2-Methyl-4-phenyl-3-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pent-3-en-2-ol (10a). A flame-dried tube equipped 
with a magnetic stir bar was charged under Ar with 1,4-dioxane (2 mL), 2-methyl-4-
phenylbut-3-yn-2-ol (32 mg, 0.2 mmol), NaHMDS (36.7 mg, 0.2 mmol), and B2Pin2 
(55.8 mg, 0.22 mol). The mixture was stirred for 2-5 min at room temperature before 
Pd2(dba)3 (9.1 mg, 0.01 mmol), tri-1-naphthylphosphine (16.5 mg, 0.04 mmol) and MeI 
(37 L, 0.6 mmol) were added. The tube was sealed and stirred at 60 oC (bath temperature) for 18 h. 
After cooling to room temperature, the reaction was quenched with aq. sat. NH4Cl (2 mL), the aqueous 
phase was extracted with EtOAc (3 x 5 mL), the combined organic layers were dried over Na2SO4 and 
filtered, and the filtrate was evaporated under vacuum. The residue was purified by flash 
chromatography (SiO2, hexanes/EtOAc) or thin layer chromatography to give the title compound as a 
colorless oil (42.3 mg, 70%). When carried out with KHMDS (39.8 mg, 0.2 mmol) instead of 
NaHMDS, the yield was 56%. 
1
H NMR (400 MHz, CD3OD) δ = 7.29-7.15 (m, 5 H), 2.12 (s, 3 H), 
1.50 (s, 6 H), 0.93 (s, 12 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 146.6, 143.3, 128.0, 127.5, 126.2, 
83.0, 72.8, 29.2, 23.7, 21.3 ppm; 
11
B NMR (128 MHz, CD3OD) δ = 29.6 ppm; IR (ATR): ṽ = 2976, 
2931, 2067, 1441, 1371, 1343, 1293, 1142, 977, 849, 765, 700, 667, 553 cm
-1
; HRMS (EI) m/z calcd 
for [C18H27BO3+Na]
+
: 325.1945; found: 325.1946.  
(E)-4-Phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pent-3-en-2-ol (10f) (Larger Scale). 
A flame-dried round bottom flask equipped with a magnetic stir bar was charged under 
Ar with 1,4-dioxane (25 mL), 4-phenylbut-3-yn-2-ol (730 mg, 5 mmol) and KHMDS 
(998 mg, 5 mmol), followed by slow addition of B2Pin2 (1.40 g, 5.5 mol) (Attention: 
exothermic!). Pd2(dba)3 (228 mg, 0.25 mmol), tri-1-naphthylphosphine (412 mg, 1.0 
mmol) and MeI (935 L, 15 mmol) were sequentially introduced and the resulting 
mixture was stirred at 60 
o
C (bath temperature) for 24 h. After cooling to room temperature, the 
reaction was quenched with aq. sat. NH4Cl (10 mL), the aqueous phase was extracted with EtOAc (3 x 
10mL), the combined organic layers were dried (Na2SO4), filtered and evaporated. The residue was 
purified by flash chromatography (SiO2, hexanes/EtOAc) to provide the title compound as a pale 
yellow oil (972 mg, 67 %). 
1
H NMR (400 MHz, CD3OD) δ = 7.33-7.15 (m, 5 H), 4.79 (q, J = 8 Hz, 1 
H), 2.01 (s, 3 H), 1.37 (d, J = 8 Hz, 3 H), 1.08 (s, 6 H), 1.01 (s, 6 H) ppm; 
13
C NMR (101 MHz, 
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CD3OD) δ = 145.7, 143.1, 127.6, 127.4, 126.5, 83.0, 67.9, 23.7, 23.6, 21.6, 18.8 ppm; 
11
B NMR (128 
MHz, CD3OD) δ = 29.9 ppm; IR (ATR): ṽ = 2976, 2928, 1629, 1372, 1354, 1293, 1140, 973, 855, 
762, 700, 670, 533 cm
-1
; HRMS (ESI) m/z calcd for [C17H25BO3+Na]
+
: 311.1789; found: 311.1789. 
The following compounds were prepared analogously: 
(E)-4-(4-Chlorophenyl)-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pent-3-en-2-ol 




H NMR (400 MHz, CD3OD) δ = 
7.30-7.24 (m, 2 H), 7.22-7.16 (m, 2 H), 2.13 (s, 3 H), 1.51 (s, 6 H), 0.98 (s, 12 H) 
ppm; 
13
C NMR (125 MHz, CD3OD) δ = 145.2, 141.9, 132.1, 129.7, 127.5, 83.1, 
72.8, 29.1, 23.6, 21.1 ppm; 
11
B NMR (128 MHz, CD3OD) δ = 29.8 ppm; IR 
(ATR): ṽ = 3451, 2975, 2930, 1619, 1481, 1372, 1335, 1288, 1214, 1164, 1141, 
1086, 1012, 923, 847, 828, 688, 648, 550 cm
-1
; HRMS (ESI) m/z calcd for 
[C18H26BClO3+Na]
+












(10c). Colorless oil (52 mg, 85%); 
1
H NMR (400 MHz, CD3OD) δ = 7.17-7.09 
(m, 2 H), 6.86-6.79 (m, 2 H), 3.77 (s, 3 H), 2.11 (s, 3 H), 1.51 (s, 6 H), 0.98 (s, 
12 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 158.7, 143.0, 139.1, 129.1, 112.9, 
83.0, 72.8, 54.4, 29.2, 23.7, 21.4 ppm; 
11
B NMR (128 MHz, CD3OD) δ = 29.9 
ppm; IR (ATR): ṽ = 2975, 2931, 1607, 1509, 1370, 1343, 1289, 1241, 1142, 1083, 1034, 980, 849, 
831, 734, 666, 557 cm
-1
; HRMS (ESI) m/z calcd for [C19H29BO4+Na]
+
: 355.2051; found: 355.2052. 
(E)-2-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(4-(trifluoromethyl)phenyl)pent-
3-en-2-ol (10d). Yellow oil (65 mg, 82%); 
1
H NMR (400 MHz, CD3OD) δ = 7.62-
7.50 (m, 2 H), 7.43-7.34 (m, 2 H), 2.16 (s, 3 H), 1.53 (s, 6 H), 0.95 (s, 12 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 150.6, 141.9, 128.7, 128.5 (q, J = 32 Hz), 124.5 
(q, J = 4 Hz), 124.4 (q, J = 270 Hz), 83.1, 72.8, 29.1, 23.6, 21.0 ppm; 
11
B NMR 
(128 MHz, CD3OD) δ = 29.7 ppm; IR (ATR): ṽ = 2977, 2933, 1614, 1372, 1323, 1297, 1162, 1123, 
1107, 1063, 1016, 927, 844, 667, 608, 539 cm
-1
; HRMS (ESI) m/z calcd for [C19H26BF3O3+Na]
+
: 
393.1819; found: 393.1820. 
(E)-4-(4-Hydroxy-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pent-2-en-2-




H NMR (400 
MHz, CD3OD) δ = 7.60-7.50 (m, 2 H), 7.33-7.21 (m, 2 H), 2.03 (s, 3 H), 1.40 (s, 
6 H), 0.86 (s, 12 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 151.6, 141.5, 131.6, 
129.2, 118.4, 109.9, 83.2, 72.9, 29.1, 23.7, 20.8 ppm; 
11
B NMR (128 MHz, 
CD3OD) δ = 29.5 ppm; IR (ATR): ṽ = 2980, 2928, 2585, 2231, 1598, 1347, 1297, 1256, 1141, 1081, 
975, 946, 843, 648, 577, 517 cm
-1
; HRMS (ESI) m/z calcd for [C19H26NO3B+Na]
+
: 350.1898; found: 
350.1899. 
(E)-2-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(thiophen-3-yl)pent-3-en-2-ol 




H NMR (400 MHz, CD3OD) δ 
= 7.19-7.14 (m, 1 H), 7.04-7.00 (m, 1 H), 6.90-6.87 (m, 1 H), 1.99 (s, 3 H), 1.39 (s, 6 
H), 0.95 (s, 12 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 147.2, 137.7, 127.7, 124.5, 
121.6, 83.2, 72.8, 29.2, 23.9, 20.8 ppm; 
11
B NMR (128 MHz, CD3OD) δ = 29.6 ppm; 
IR (ATR): ṽ = 2972, 2929, 2557, 1619, 1370, 1340, 1290, 1142, 1086, 978, 852, 793, 664, 636, 521 
cm
-1
; HRMS (ESI) m/z calcd for [C16H25O3BS+Na]
+
: 331.1510; found: 331.1511. 
(E)-3-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(o-tolyl)hex-4-en-3-ol (10h). 
Colorless oil (50 mg, 77%); 
1
H NMR (400 MHz, CD3OD) δ = 7.12-6.95 (m, 4 H), 
2.29 (d, J = 2.8 Hz, 3 H), 2.02 (d, J = 3.2 Hz, 3 H), 1.97-1.82 (m, 1 H), 1.82-1.67 
(m, 1 H), 1.48 (d, J = 4.0 Hz, 3 H), 1.06 (dt, J = 1.2, 7.6 Hz, 3 H), 0.87 (d, J = 2.5 
Hz, 6 H), 0.83 (s, 6 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 145.65, 145.63, 
142.5, 142.3, 135.42, 135.39, 129.34, 129.32, 128.96, 128.92, 126.3, 124.89, 124.88, 82.6, 75.57, 
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75.55, 34.84, 34.82, 27.36, 27.19, 23.58, 23.56, 23.34, 23.30, 20.84, 20.76, 18.27, 18.16, 7.56, 7.50 
ppm; 
11
B NMR (128 MHz, CD3OD) δ = 29.7 ppm; IR (ATR): ṽ = 2977, 2930, 2069, 1372, 1346, 
1292, 1144, 1122, 1078, 976, 851, 769, 727, 668 cm
-1
; HRMS (ESI) m/z calcd for [C20H31BO3+Na]
+
: 
353.2258; found: 353.2259. 
(8R,9S,13S,14S,17R)-17-((E)-2-(4-Chlorophenyl)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)prop-1-en-1-yl)-3-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta-





(400 MHz, CD3OD) δ = 7.31-7.23 (m, 2 H), 7.23-7.13 (m, 3 H), 
6.70-6.61 (m, 1 H), 6.61-6.54 (m, 1 H), 3.73 (s, 3 H), 2.9-2.71 (m, 
2 H), 2.52-2.40 (m, 1 H), 2.39-2.28 (m, 1 H), 2.18 (s, 3 H), 2.16-
2.07 (m, 1 H), 1.98-1.67 (m, 6 H), 1.52-1.22 (m, 4 H), 1.00 (s, 3 
H), 0.96 (s, 6 H), 0.92 (s, 6 H) ppm; 
13
C NMR (101 MHz, 
CD3OD) δ = 157.5, 148.0, 146.1, 137.4, 132.4, 132.2, 130.1, 
127.6, 125.8, 113.2, 111.1, 86.4, 82.9, 54.1, 49.0, 48.4, 43.5, 40.0, 38.7, 33.7, 29.5, 27.3, 26.7, 24.8, 
24.1, 23.7, 13.6 ppm; 
11
B NMR (128 MHz, CD3OD) δ = 30.6 ppm; IR (ATR): ṽ = 2976, 2930, 1609, 
1499, 1335, 1253, 1141, 1092, 1014, 982, 850, 830, 697, 548 cm
-1
; HRMS (ESI) m/z calcd for 
[C34H43BClO4]
-
: 561.2948; found: 561.2943. 
(3E,5Z)-4,8-Dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nona-3,5-dien-2-ol (10j). 
Colorless oil (29 mg, 60%); 
1
H NMR (400 MHz, CD3OD) δ = 6.01 (d, J = 12 Hz, 1 
H), 5.34-5.17 (m, 1 H), 4.57 (q, J = 8 Hz, 1 H), 2.00-1.80 (m, 2 H), 1.67 (s, 3 H), 
1.56-1.42 (m, 1 H), 1.20 (d, J = 8 Hz, 3 H), 1.15 (s, 12 H), 0.79 (d, J = 8 Hz, 3 H), 
0.78 (d, J = 8 Hz, 3 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 139.9, 133.3, 
129.8, 83.0, 67.4, 37.6, 28.5, 23.9, 23.6, 21.7, 21.6, 21.4, 17.4 ppm; 
11
B NMR (128 
MHz, CD3OD) δ = 30.6 ppm; IR (ATR): ṽ = 2956, 2929, 1465, 1371, 1352, 1291, 1143, 1107, 975, 
855, 732, 672, 517 cm
-1
; HRMS (ESI) m/z calcd for [C17H31BO3+Na]
+
: 317.2258; found: 317.2259. 
(E)-6,6,6-Trifluoro-5-methyl-1-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hex-4-en-3-
ol (10k). Colorless oil (39 mg, 66%); 
1
H NMR (400 MHz, CD3OD) δ = 7.30-7.19 
(m, 4 H), 7.19-7.12 (m, 1 H), 4.50-4.41 (m, 1 H), 2.84-2.73 (m, 1 H), 2.72-2.60 
(m, 1 H), 2.09-1.96 (m, 1 H), 1.76-1.65 (m, 1 H), 1.60 (s, 3 H), 1.30 (s, 6 H), 1.29 
(s, 6 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 141.7, 128.2, 128.0, 127.2 (q, J = 
29 Hz), 125.4, 124.4 (q, J = 270 Hz), 84.0, 69.7, 37.3, 31.2, 23.9, 23.8, 10.9 ppm; 
11
B NMR (128 
MHz, CD3OD) δ = 30.1 ppm; IR (ATR): ṽ = 2979, 2930, 1661, 1454, 1357, 1313, 1165, 1137, 1102, 
1021, 847, 748, 699, 531 cm
-1
; HRMS (ESI) m/z calcd for [C19H26BF3O3+Na]
+






less oil (49 mg, 63%); 
1
H NMR (400 MHz, CD3OD) δ = 4.67-4.63 (m, 1 H), 
4.59-4.55 (m, 1 H), 4.31 (t, J = 8 Hz, 1 H), 1.73 (q, J = 0.8 Hz, 3 H), 1.65 (s, 3 
H), 1.61-1.40 (m, 2 H), 1.33-1.18 (m, 6 H), 1.13 (s, 12 H), 0.81 (t, J = 8 Hz, 3 H) 
ppm; 
13
C NMR (101 MHz, CD3OD) δ = 150.4, 146.6, 111.7, 82.9, 71.1, 36.6, 
31.7, 25.2, 23.8, 23.7, 22.3, 20.0, 15.7, 13.0 ppm; 
11
B NMR (128 MHz, CD3OD) δ = 30.6 ppm; IR 
(ATR): ṽ = 2929, 2858, 1628, 1446, 1371, 1354, 1293, 1166, 1142, 1009, 964, 895, 859, 687, 669, 564 
cm
-1
; HRMS (ESI) m/z calcd for [C18H33BO3+Na]
+
: 331.2415; found: 331.2412. 
(E)-6,9-Dimethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)dec-6-en-4-yne-1,8-diol (10m). Colorless 
oil (30 mg, 48 %, using 2 equiv. NaHMDS and 2.2 equiv. B2Pin2); 
1
H 
NMR (400 MHz, CD3OD) δ = 3.94 (d, J = 8.4 Hz, 1 H), 3.54 (t, J = 6.4 
Hz, 2 H), 2.29 (t, J = 7.2 Hz, 2 H), 1.74 (s, 3 H), 1.72-1.67 (m, 1 H), 1.67-
1.60 (m, 2 H), 1.20 (s, 12 H), 0.91 (d, J = 6.8 Hz, 3 H), 0.71 (d, J = 6.8 Hz, 
3 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 126.4, 89.6, 83.4, 83.2, 76.4, 60.4, 33.7, 31.3, 23.8, 23.7, 
19.1, 18.4, 18.1, 15.4 ppm; 
11
B NMR (128 MHz, CD3OD) δ = 30.6 ppm; IR (ATR): ṽ = 3439, 2974, 
2932, 2872, 1607, 1442, 1379, 1324, 1304, 1139, 1008, 854, 672, 578 cm
-1
; HRMS (ESI) m/z calcd for 
[C18H31BO4+Na]
+
: 345.2208; found: 345.2209. 
(E)-2,4-Dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)undec-3-en-5-yn-2-ol (10n). 
Colorless oil (39 mg, 60%); 
1
H NMR (400 MHz, CD3OD) δ = 2.26 (t, J = 8 
Hz, 2 H), 1.96 (s, 3 H), 1.56-1.46 (m, 2 H), 1.44-1.32 (m, 10 H), 1.30 (s, 12 
H), 0.92 (t, J = 8 Hz, 3 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 123.5, 
88.3, 84.0, 83.4, 72.6, 30.9, 28.9, 28.3, 23.9, 21.9, 20.1, 18.8, 12.9 ppm; 
11
B 
NMR (128 MHz, CD3OD) δ = 29.9 ppm; IR (ATR): ṽ = 2975, 2931, 2860, 1592, 1465, 1371, 1348, 
1294, 1165, 1143, 976, 928, 855, 668, 554 cm
-1
; HRMS (ESI) m/z calcd for [C19H33BO3+Na]
+
: 
343.2415; found: 343.2415. 
(E)-5-(Cyclohex-1-en-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hex-4-en-3-ol (10o). 
Colorless oil (33 mg, 69%); 
1
H NMR (400 MHz, CD3OD) δ = 5.47-5.38 (m, 1 H), 
4.35 (t, J = 8 Hz, 1 H), 2.21-1.97 (m, 4 H), 1.74 (s, 3 H), 1.72-1.55 (m, 6 H), 1.26 
(s, 12 H), 0.91 (t, J = 8 Hz, 3 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 148.1, 
144.2, 122.1, 82.8, 72.8, 29.5, 26.7, 24.8, 24.1, 23.9, 22.4, 21.8, 16.0, 9.4 ppm; 
11
B 
NMR (128 MHz, CD3OD) δ = 30.5 ppm; IR (ATR): ṽ = 2977, 2929, 2876, 2068, 1623, 1378, 1353, 
1291, 1131, 1081, 977, 918, 857, 699, 563 cm
-1
; HRMS (ESI) m/z calcd for [C18H31BO3+Na]
+
: 
329.2258; found: 329.2261. 
(2E,5E,7E)-3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(3-
(trifluoromethyl)phenyl)nona-2,5,7-trien-4-ol (10p). Yellow oil (56 
mg, 68%, contains 8 % of the 2E,5Z,7Z-isomer); 1H NMR (400 MHz, 
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CD3OD) δ = 7.62-7.42 (m, 4 H), 6.36-6.19 (m, 1 H), 6.19-6.02 (m, 1 H), 5.93-5.52 (m, 2 H), 5.08 (d, J 
= 8 Hz, 1 H), 2.06 (s, 3 H), 1.82-1.74 (m, 3 H), 1.06 (s, 6 H), 1.01 (s, 6 H) ppm; 
13
C NMR (101 MHz, 
CD3OD) δ = 146.6, 143.7, 131.3, 131.2, 131.1, 130.4, 129.8 (q, J = 31 Hz), 129.1, 128.4, 124.4 (q, J = 
270 Hz), 124.3 (q, J =4 Hz), 123.2 (q, J =4 Hz), 83.2, 72.6, 23.6, 23.5, 19.3, 16.9 ppm; 
11
B NMR (128 
MHz, CD3OD) δ = 30.2 ppm; IR (ATR): ṽ = 2977, 2931, 2058, 1575, 1361, 1329, 1309, 1119, 1076, 
986, 850, 804, 696, 663 cm
-1
; HRMS (ESI) m/z calcd for [C22H28BF3O3+Na]
+
: 431.1976; found: 
431.1976. 
Representative Procedure for trans-Allylboration. Preparation of (E)-4-(4-Methoxyphenyl)-2-
methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hepta-3,6-dien-2-ol (11). A flame-dried 
glass tube equipped with a magnetic stir bar was charged under Ar with 1,4-
dioxane (2.5 mL), 2-methyl-4-(4-methoxyphenyl)but-3-yn-2-ol (48.2 mg, 0.253 
mmol), NaHMDS (46.5 mg, 0.253 mmol), and B2Pin2 (71.1 mg, 0.28 mol). The 
mixture was stirred for 2-5 minutes at room temperature before Pd(PtBu3)2 (12.7 
mg, 0.025 mmol) and allyl bromide (65 L, 0.75 mmol) were added. The tube 
was sealed and the mixture stirred at 75 
o
C (bath temperature) for 18 h. After cooling to room 
temperature, the reaction was quenched with aq. sat. NH4Cl (2 mL), the aqueous phase was extracted 
by EtOAc (3 x 5 mL), and the combined organic layer were dried (NaSO4), filtered and evaporated. 
The residue was purified by flash chromatography (SiO2, hexanes/acetone), affording the title 
compound as a colorless oil (60 mg, 66 %). 
1
H NMR (400 MHz, CD3OD) δ = 7.12-7.02 (m, 2 H), 
6.83-6.74 (m, 2 H), 5.70-5.55 (m, 1 H), 4.90-4.85 (m, 1 H), 4.84-4.82 (m, 1 H), 3.75 (s, 3 H), 3.41-
3.33 (m, 2 H), 1.50 (s, 6 H), 0.94 (s, 12 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 158.7, 144.9, 
136.5, 135.7, 130.2, 114.8, 112.6, 83.0, 72.7, 54.3, 39.3, 29.9, 23.7 ppm; 
11
B NMR (128 MHz, 
CD3OD) δ = 29.6 ppm; IR (ATR): ṽ = 2976, 2932, 1606, 1509, 1463, 1348, 1291, 1242, 1175, 1143, 
1109, 1034, 909, 832, 808, 732, 666, 553, 512 cm
-1
; HRMS (ESI) m/z calcd for [C21H31BO4+Na]
+
: 
381.2208; found: 381.2209. 
(E)-4-(4-Chlorophenyl)-2-methyl-5-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pent-
3-en-2-ol (12). Prepared according to the representative procedure using benzyl 




H NMR (400 
MHz, (CD3)2CO) δ = 7.18-6.99 (m, 9 H), 4.13 (s, 2 H), 3.86 (brs, OH), 1.57(s, 6 H), 
0.94 (s, 12 H) ppm; 
13
C NMR (101 MHz, (CD3)2CO) δ = 143.6, 143.0, 139.5, 131.6, 
131.2, 129.2, 127.8, 127.1, 125.5, 82.8, 72.6, 39.9, 31.1, 24.2 ppm; 
11
B NMR (128 MHz, (CD3)2CO) δ 
= 29.9 ppm; IR (ATR): ṽ = 2975, 2932, 1601, 1484, 1349, 1298, 1203, 1141, 1085, 1014, 980, 848, 
724, 700, 548, 460 cm
-1
; HRMS (ESI) m/z calcd for [C24H30BClO3+Na]
+




Representative Procedure for trans-Alkynylboration. Preparation of (Z)-4-(4-chlorophenyl)-2-
methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-(triisopropylsilyl)hex-3-en-5-yn-2-ol 
(13a). A flame-dried tube equipped with a magnetic stir bar was charged under Ar 
with THF (0.2 mL), toluene (2 mL), 2-methyl-4-(4-chlorophenyl)but-3-yn-2-ol 
(38.8 mg, 0.2 mmol,), NaHMDS (36.7 mg, 0.2 mmol,), and B2Pin2 (55.8mg, 0.22 
mol). The mixture was stirred for 2 minutes at room temperature before Pd2(dba)3 
(9.1 mg, 0.01 mmol), tri(2-furyl)phosphine (9.2 mg, 0.04 mmol) and (bromoethynyl)triisopropylsilane 
(156 mg, 0.6 mmol) were added. The flask was sealed and the mixture stirred at 75 
o
C (bath 
temperature) for 20 h. After cooling to room temperature, the reaction was quenched with aq. sat. 
NH4Cl (2  mL), the aqueous phase was extracted by EtOAc (3 x 5 mL), and the combined organic 
layer were dried (NaSO4), filtered and evaporated. The residue was purified by flash chromatography 




H NMR (400 MHz, (CD3)2CO) δ = 7.39-7.33 (m, 2 H), 7.27-7.21 (m, 2 H), 3.93 (s, 1 H), 1.57 (s, 
6 H), 0.98-0.93 (m, 33 H) ppm; 
13
C NMR (101 MHz, CD2Cl2) δ = 140.3, 132.8, 130.2, 127.9, 124.0, 
106.3, 99.9, 83.4, 74.1, 28.1, 24.2, 18.1, 11.3 ppm; 
11
B NMR (128 MHz, CD2Cl2) δ = 29.5 ppm; IR 
(ATR): ṽ = 2943, 2865, 2129, 1584, 1463, 1360, 1326, 1303, 1142, 1086, 1014, 998, 939, 883, 806, 
677, 663, 618, 560 cm
-1
; HRMS (ESI) m/z calcd for [C28H44BSiClO3+Na]
+




The following compound was prepared analogously: 
(Z)-6-(tert-Butyldimethylsilyl)-4-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hex-3-en-




H NMR (400 MHz, 
CD3OH) δ = 7.46-7.36 (m, 2 H), 7.34-7.22 (m, 3 H), 5.09 (q, J = 6.4 Hz, 1 H), 1.43 








C NMR (101 MHz, CD3OD) δ = 139.9, 127.8, 127.76, 127.71, 127.5, 103.6, 99.8, 83.8, 
71.1, 25.2, 23.8, 23.7, 21.2, 16.1, -5.81, -5.83 ppm; 
11
B NMR (128 MHz, CD3OH) δ = 30.6 ppm; IR 
(ATR): ṽ = 2977, 2929, 1590, 1354, 1305, 1250, 1141, 1058, 976, 824, 812, 769, 698, 672, 606 cm-1; 
HRMS (ESI) m/z calcd for [C24H37BSiO3+Na]
+




 Prepared by adaptation of a literature procedure:
[6]
 A mixture of 
compound 10f (34.8 mg, 0.12 mmol), AgNO3 (2 mg, 0.012 mmol, 10 mol %), NEt3 
(16 mg, 0.16 mmol) in EtOH/H2O (0.5 mL/0.5 mL) was stirred at 80 °C for 3 h under 
air. The reaction was quenched with brine (5 mL) and the aqueous phase extracted 
with ethyl acetate (5 mL × 3). The combined organic layers were dried over Na2SO4, filtered and 
evaporated under vacuum. The residue was purified by flash chromatography on silica gel to afford 
the product as a colorless oil (16.2 mg, 83%). 
1
H NMR (400 MHz, CD2Cl2) δ = 7.35-7.28 (m, 2 H), 
7.26-7.19 (m, 2 H), 7.18-7.12 (m, 1 H), 5.69 (dq, J = 1.2 and 8.0 Hz, 1 H), 4.69-4.58 (m, 1 H), 1.99 (d, 
J = 1.2 Hz, 3 H), 1.21 (d, J = 6.0 Hz, 3 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 143.0, 135.7, 
132.2, 128.2, 127.1, 125.7, 65.0, 23.3, 15.8 ppm.  
(E)-3-(4-Chlorophenyl)-4-phenylpent-3-en-2-ol (15). Prepared by adaptation of a literature 
procedure:
[8]
 A flame-dried Schlenk flask was charged with compound 10f (0.157 
mmol, 45.2 mg) and THF (2 mL). Pd(Pt-Bu3)2 (8 mg, 10 mol %), 1-chloro-4-
iodobenzene (45.3 mg, 0.19 mmol), solid NaOH (18.8 mg, 0.47 mmol) and H2O (8.5 
µL) were added under Ar and the resulting mixture was stirred at 50 ºC for 12 h. After 
evaporation of all volatile materials, the crude product was purified by flash 
chromatography on silica gel to offer the title compound as a pale yellow solid (28.4 




H NMR (400 MHz, CD2Cl2) δ = 7.03-6.97 (m, 4 H), 6.96-6.92 (m, 1 H), 
6.92-6.83 (m, 4 H), 5.04 (q, J = 6.4 Hz, 1 H), 2.09 (s, 3 H), 1.13 (d, J = 6.4 Hz, 3 H) ppm; 
13
C NMR 
(101 MHz, CD2Cl2) δ = 144.0, 139.7, 137.5, 135.7, 132.5, 131.8, 128.5, 127.6, 127.3, 125.9, 66.8, 
22.0, 20.1 ppm; IR (ATR): ṽ = 3273, 2926, 1488, 1442, 1129, 1069, 1015, 940, 835, 763, 699, 603, 
508 cm
-1
; HRMS (EI) m/z calcd for [C17H17OCl]
+
: 272.0968; found: 272.0963. 
2-Hydroxy-4-phenylpentan-3-one (16). Prepared by adaptation of a literature procedure:
[6]
: A mixture of 
compound 10f (46.2 mg, 0.16 mmol), NaBO3
.
H2O (128 mg, 0.64 mmol) and THF/H2O 
(2 mL/2 mL) was stirred at room temperature for 3 h. The reaction was quenched with 
brine (5 mL) and the aqueous phase was extracted with ethyl acetate (3 x 5 mL). The 
combined organic layers were dried over anhydrous Na2SO4, filtered and evaporated under vacuum. 
The crude product was purified by flash chromatography on silica gel to afford the title compound as a 
colorless oil (20 mg, 70 %, dr = 3.3 :1). 
1
H NMR (400 MHz, CD2Cl2) δ = 7.28-7.21 (m, 2 H), 7.21-
7.09 (m, 3 H), 4.31-4.04 (m, 1 H), 3.98-3.84 (m, 1 H), 3.18 (brs, OH), 1.37-1.30 (m, 3 H), 1.28-1.04 
(m, 3 H) ppm; 
13
C NMR (101 MHz, CD2Cl2) δ = 212.8, 140.0, 129.0, 128.7, 127.84, 127.82, 127.4, 
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127.2, 72.7, 70.9, 47.8, 47.7, 19.9, 19.7, 19.2, 17.5 ppm; IR (ATR): ṽ = 3400, 2979, 2935, 1713, 1447, 
1367, 1149, 1073, 1009, 899, 698 cm
-1
; HRMS (ESI) m/z calcd for [C11H14O2+Na]
+
: 201.0886; found: 
201.0887. 
(S*)-1-((2S*,3S*)-3-Methyl-3-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxiran-2-
yl)ethan-1-ol (17). Prepared by adaptation of a literature procedure:
[7]
 A flame-dried Schlenk flask 
was charged with compound 10f (40.5 mg, 0.14 mmol), CH2Cl2 (2 mL) and VO(acac)2 
(5.6 mg, 15 mol %) under Ar. The resulting greenish-blue solution was cooled to –20 ºC 
before a solution of tert-butyl hydroperoxide (5.0 M solution in decane, 84 µL, 0.42 
mmol) was added dropwise at this temperature. The mixture was stirred at –20 ºC for 20 h before it 
was filtered through a pad of Celite. The filtrate was evaporated and the residue was rapidly purified 
by flash chromatography on silica gel to afford the title compound as a white solid (28.5 mg, 66 %). 
mp: 130-131 ºC; 
1
H NMR (400 MHz, CD2Cl2) δ = 7.30-7.22 (m, 2 H), 7.22-7.16 (m, 2 H), 7.16-7.09 
(m, 1 H), 3.66-3.55 (m, 1 H), 2.32-2.22 (m, 1 H), 1.62 (s, 3 H), 1.25 (d, J = 6.4 Hz, 3 H), 0.85 (s, 6 H), 
0.76 (s, 6 H) ppm; 
13
C NMR (101 MHz, CD2Cl2) δ = 142.4, 127.8, 127.1, 126.1, 84.2, 68.6, 65.2, 24.2, 
24.1, 21.5, 19.8 ppm; 
11
B NMR (128 MHz, CD3OD) δ = 30.5 ppm; IR (ATR): ṽ = 3473, 2977, 2921, 
1449, 1316, 1276, 1141, 1086, 1057, 982, 851, 780, 703, 661, 551 cm
-1
; HRMS (ESI) m/z calcd for 
[C17H25BO4+Na]
+
: 327.1738; found: 327.1739. 
2-(1,1-Dimethyl-3-(4-(trifluoromethyl)phenyl)-1H-inden-2-yl)-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane (18). Prepared by adaptation of a literature procedure:
[9b] 
Sc(OTf)3 (2.46 mg, 5 mol%) was added to a solution of compound 5c (43 mg, 
0.1 mmol,) in 1,2-dichloroethane (2 mL) and the resulting mixture was stirred 
at 50 
o
C for 1 h. The solvent was removed in vacuo and the residue was 
purified by flash chromatography on silica gel to afford the title compound as a white solid (38.1 mg, 




H NMR (400 MHz, CD2Cl2) δ = 7.62-7.56 (m, 2 H), 7.53-7.46 (m, 2 H), 
7.36-7.30 (m, 1 H), 7.23-7.09 (m, 3 H), 1.36 (s, 6 H), 1.12 (s, 12 H) ppm; 
13
C NMR (101 MHz, 
CD2Cl2) δ = 156.9, 151.4, 142.3, 140.3 (d, J = 1.5 Hz), 129.7, 129.3 (q, J = 32 Hz), 126.6, 126.4, 
124.6 (q, J = 3.9 Hz), 124.5 (q, J = 270 Hz), 121.5, 121.0, 83.1, 52.6, 24.4, 24.3 ppm;
 11
B NMR (128 
MHz, CD2Cl2) δ = 30.1 ppm; IR (ATR): ṽ = 2971, 2928, 1591, 1575, 1369, 1321, 1307, 1265, 1120, 
1105, 1064, 1016, 852, 759, 719, 673, 634 cm
-1
; HRMS (ESI) m/z calcd for [C24H26BF3O2+Na]
+
: 
437.1870; found: 437.1874.  
2-(2,5-Dimethyl-4-phenylfuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (19). Prepared by 
adaptation of a literature procedure:
[9a]
 AuCl3 (1.5 mg, 5 mol%) was added to a solution 
of (Z)-enynol 13b (0.11 mmol, 46 mg) in 1,2-dichloroethane (2 mL) and the resulting 
mixture was stirred at room temperature for 2 h. The solvent was removed in vacuo 
and the residue was purified by flash chromatography on silica gel to afford the title 
compound as a colorless oil (19.6 mg, 65 %). 
1
H NMR (400 MHz, CD3OD) δ = 7.48-7.26 (m, 5 H), 
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2.52 (s, 3 H), 2.32 (s, 3 H), 1.33 (s, 12 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 159.7, 146.1, 134.6, 
129.4, 127.1, 125.8, 125.1, 82.7, 23.6, 12.6, 10.5 ppm;
 11
B NMR (128 MHz, CD3OD) δ = 30.2 ppm; 
IR (ATR): ṽ = 2977, 2921, 1577, 1413, 1341, 1302, 1141, 1055, 994, 846, 758, 698, 663 cm-1; HRMS 
(ESI) m/z calcd for [C18H23BO3+Na]
+
: 321.1632; found: 321.1633. 
4-(4-(2-Chloroethoxy)phenyl)but-3-yn-2-ol (20). Prepared according to a literature procedure.
[4]
 




H NMR (400 MHz, CD3OD) δ = 
7.40-7.30 (m, 2 H), 6.96-6.86 (m, 2 H), 4.67 (q, J = 6.4 Hz, 1 H), 4.25 (t, J = 5.6 
Hz, 2 H), 3.86 (t, J = 5.6 Hz, 2 H), 148 (d, J = 6.4 Hz, 3 H) ppm; 
13
C NMR (101 
MHz, CD3OD) δ = 158.4, 132.6, 115.6, 114.3, 89.6, 82.5, 68.1, 57.6, 41.8, 23.4 ppm;
 
IR (ATR): ṽ = 
3393, 2981, 1609, 1510, 1453, 1289, 1254, 1179, 1110, 1036, 933, 827, 666 cm
-1
; HRMS (EI) m/z 
calcd for [C12H13O2Cl+Na]
+
: 247.0496; found: 247.0495.  
(Z)-4-(4-Bromophenyl)-4-(4-(2-chloroethoxy)phenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)but-3-en-2-ol (21). A flame-dried Schlenk-tube equipped with a magnetic 
stir bar was charged under Ar with THF (0.24 mL), 4-(4-(2-
chloroethoxy)phenyl)but-3-yn-2-ol 20 (67.5 mg, 0.3 mmol), and NaHMDS 
(55.8 mg, 0.3 mmol). B2Pin2 (83.8 mg, 0.33 mmol), 1,2-dichloroethane (3 ml), 
Pd2(dba)3 (13.7 mg, 0.015 mmol), tri(2-furyl)phosphine (13.9 mg, 0.06 mmol) 
and bis(4-bromophenyl)iodonium triflate (352 mg, 0.6 mmol) were sequentially added, the tube was 
sealed and the mixture stirred at 60 
o
C (bath temperature) for 18 h. After cooling to room temperature, 
the reaction was quenched with aq. sat. NH4Cl (2 mL), the aqueous phase was extracted with EtOAc 
(3 × 5mL), and the combined organic layers were dried (NaSO4), filtered and evaporated. The residue 
was purified by flash chromatography (SiO2, hexanes/EtOAc) to provide the title compound as a white 




H NMR (400 MHz, CD3OD) δ = 7.53-7.43 (m, 2 H), 7.13-7.01 
(m, 4 H), 6.87-6.80 (m, 2 H), 4.44 (q, J = 6.4 Hz, 1 H), 4.20 (t, J = 5.6 Hz, 2 H), 3.81 (t, J = 5.6 Hz, 2 
H), 1.28 (d, J = 6.4 Hz, 3 H), 1.19 (s, 6 H), 1.13 (s, 6 H) ppm; 
13
C NMR (101 MHz, CD3OD) δ = 
158.1, 147.3, 141.0, 136.6, 131.0, 130.6, 130.0, 120.6, 113.8, 83.5, 68.9, 68.1, 41.8, 23.9, 23.7, 21.9 
ppm; 
11
B NMR (128 MHz, CD3OD) δ = 32.0 ppm; IR (ATR): ṽ = 2975, 2924, 1605, 1508, 1484, 
1352, 1299, 1242, 1132, 1069, 1010, 961, 882, 850, 828, 814, 757, 671, 617 cm
-1
; HRMS (ESI) m/z 
calcd for [C24H29BBrClO4+Na]
+
: 529.0923; found: 529.0932.  
(Z)-4-(4-Bromophenyl)-4-(4-(2-chloroethoxy)phenyl)-3-phenylbut-3-en-2-ol (S8). A flame-dried 
Schlenk flask was charged with compound 21 (0.065 mmol, 33 mg) and THF 
(0.6 mL). Pd(dppf)Cl2 (4.7 mg, 10 mol %), iodobenzene (15 µL, 0.134 mmol), 
aq. KOH (9 M, 29 µL, 0.26 mmol) were added under Ar atmosphere and the 
resulting mixture was stirred at room temperature for 6 h. After evaporation of 
all volatile materials, the crude product was purified by flash chromatography 




H NMR (400 MHz, CD3OD) 
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δ = 7.63-7.42 (m, 2 H), 7.30-7.06 (m, 7 H), 6.90-6.75 (m, 2 H), 6.63-6.50 (m, 2 H), 4.75 (q, J = 6.4 
Hz, 1 H), 4.07 (t, J = 5.6 Hz, 2 H), 3.74 (t, J = 5.6 Hz, 2 H), 1.13 (d, J = 6.4 Hz, 3 H) ppm; 
13
C NMR 
(101 MHz, CD3OD) δ = 156.7, 142.6, 141.2, 139.3, 138.5, 134.8, 131.23, 131.21, 131.1, 130.9, 126.9, 
126.0, 120.5, 113.2, 67.8, 67.0, 41.8, 20.5 ppm; IR (ATR): ṽ = 2966, 2925, 1604, 1507, 1485, 1238, 
1173, 1070, 1010, 827, 759, 701, 666 cm
-1
; HRMS (ESI) m/z calcd for [C24H22BrClO2+Na]
+
: 
479.0384; found: 479.0387.  
-Hydroxyidoxifene (22).[11] A Schlenk flask was charged with compound S1 (0.04 mmol, 18.3 mg), 
EtOH (0.15 mL) and pyrrolidine (0.15 mL) and the resulting mixture was 
stirred at reflux temperature overnight. After reaching ambient 
temperature, all volatile materials were evaporated. CuI (1.5 mg, 0.008 
mmol), NaI (30 mg, 0.2 mmol), 1,4-dioxane (0.3 mL) and N,N
’
-
dimethylethane-1,2-diamine (1.8 µL, 0.016mmol) were added under Ar 
and the resulting mixture was stirred at 110 
o
C (bath temperature) for 18 h. 
The mixture was allowed to cool before it was filtered through a short plug of silica. The filtrate was 
concentrated and the residue purified by thin layer chromatography to give the title compound as a 




H NMR (300 MHz, CD3OD) δ = 7.80-7.64 (m, 2 H), 
7.30-7.10 (m, 5 H), 7.10-6.99 (m, 2 H), 6.87-6.75 (m, 2 H), 6.64-6.48 (m, 2 H), 4.75 (q, J = 6.6 Hz, 1 
H), 3.96 (t, J = 5.7 Hz, 2 H), 2.81 (t, J = 5.7 Hz, 2 H), 2.69-2.50 (m, 4 H), 1.87-1.69 (, m, 4 H), 1.13 
(d, J = 6.6 Hz, 3 H) ppm; 
13
C NMR (75 MHz, CD3OD) δ = 158.5, 143.8, 143.2, 140.9, 139.9, 138.4, 
135.8, 132.7, 132.6, 132.5, 128.3, 127.4, 114.4, 93.0, 68.4, 67.4, 55.9, 55.5, 24.1, 21.9 ppm; IR 
(ATR): ṽ = 2964, 2925, 2806, 1604, 1507, 1480, 1281, 1242, 1109, 1052, 1006, 911, 826, 759, 736, 
700 cm
-1
; HRMS (EI) m/z calcd for [C28H30INO2+H]
+
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